What This Means
This research suggests that routinely prescribing blood thinners (direct oral anticoagulants, or DOACs) to all patients whose implanted heart devices detect subclinical atrial fibrillation (a type of irregular heart rhythm) is unlikely to be a cost-effective use of healthcare resources. Using a computer simulation of 20,000 patients based on real clinical trial data, the researchers found that while DOACs do provide a small health benefit (about 0.016 additional quality-adjusted life years per patient), the cost per unit of benefit gained far exceeds the commonly accepted threshold of €50,000 per quality-adjusted life year, coming in at over €105,000 in the main analysis.
The findings become more nuanced when patient risk is taken into account. Patients with higher CHA2DS2-VASc scores — a clinical scoring system that estimates stroke risk based on factors like age, heart failure, diabetes, and prior stroke — were more likely to receive cost-effective treatment. Among patients with the highest risk scores (greater than 4), there was a 52% probability that treatment would be cost-effective, compared to just 31% for lower-risk patients. However, even in this high-risk group, the evidence remained uncertain.
This research matters because implanted cardiac devices are increasingly common and frequently detect these silent episodes of atrial fibrillation, creating pressure on clinicians to act. This study suggests that a one-size-fits-all approach of treating everyone with detected subclinical AF may not represent good value for healthcare systems, and that treatment decisions may need to be more carefully targeted toward patients at the highest stroke risk. The results are based on Nordic healthcare costs and may not directly apply to other healthcare systems with different cost structures.